Agios Pharmaceuticals, Inc.
AGIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Agios Pharmaceuticals, Inc. (AGIO) is listed under Biotechnology. The $2.00B market capitalization puts AGIO squarely in mid-cap range for its industry. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Market Cap
$2.00B
Beta
0.60
P/E (TTM)
—
P/E (Fwd)
-8.50
EPS (TTM)
$-7.00
EPS (Fwd)
$-3.95
ROE
-34.3%
ROA
-22.2%
Cash
$617.6M
Total Debt
$31.2M
Free CF
-$274.6M
52W Change
-7.2%
Annual Financials
Cash vs Debt
Where AGIO stands vs its 150-day and 200-day moving averages
As of the August 21, 2026 close, AGIO finished 8.31% above its 150-day moving average ($31.05) and 8.62% above its 200-day moving average ($30.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AGIO overbought or oversold?
At the August 21, 2026 close, AGIO's RSI(14) was 72.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Agios Pharmaceuticals, Inc. holds $617.6M in cash against $31.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$274.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -34.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $14.2M (2022) to $54.0M (2025), reflecting a 279% increase over the period.
The relatively low beta of 0.60 suggests AGIO is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, AGIO has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing AGIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.